Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...

CureVac NV (CVAC) reports a robust financial position with a significant licensing agreement with GSK, despite challenges in ...

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational ...

Algernon Pharmaceuticals (AGNPF) announces that it has received a notice of allowance from the European Patent Office, EPO, for patent ...

Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical ...

The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company has previously announced the ...

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

Europe’s Unified Patent Court has ordered Kodak to stop selling its Sonora XTRA-3 process-free plates in Germany in a ruling handed down on 2 April, which Kodak is appealing.

Scotland is fortunate to have an abundance of world class higher education facilities within a relatively small geographic space. They innovate ...

Welcome to CureVac fourth-quarter and full year 2024 financial results and business update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to ...